Structural basis for the sequence-dependent effects of platinum-DNA adducts
- PMID: 19255091
- PMCID: PMC2677858
- DOI: 10.1093/nar/gkp029
Structural basis for the sequence-dependent effects of platinum-DNA adducts
Abstract
The differences in efficacy and molecular mechanisms of platinum based anti-cancer drugs cisplatin (CP) and oxaliplatin (OX) have been hypothesized to be in part due to the differential binding affinity of cellular and damage recognition proteins to CP and OX adducts formed on adjacent guanines in genomic DNA. HMGB1a in particular exhibits higher binding affinity to CP-GG adducts, and the extent of discrimination between CP- and OX-GG adducts is dependent on the bases flanking the adducts. However, the structural basis for this differential binding is not known. Here, we show that the conformational dynamics of CP- and OX-GG adducts are distinct and depend on the sequence context of the adduct. Molecular dynamics simulations of the Pt-GG adducts in the TGGA sequence context revealed that even though the major conformations of CP- and OX-GG adducts were similar, the minor conformations were distinct. Using the pattern of hydrogen bond formation between the Pt-ammines and the adjacent DNA bases, we identified the major and minor conformations sampled by Pt-DNA. We found that the minor conformations sampled exclusively by the CP-GG adduct exhibit structural properties that favor binding by HMGB1a, which may explain its higher binding affinity to CP-GG adducts, while these conformations are not sampled by OX-GG adducts because of the constraints imposed by its cyclohexane ring, which may explain the negligible binding affinity of HMGB1a for OX-GG adducts in the TGGA sequence context. Based on these results, we postulate that the constraints imposed by the cyclohexane ring of OX affect the DNA conformations explored by OX-GG adduct compared to those of CP-GG adduct, which may influence the binding affinities of HMG-domain proteins for Pt-GG adducts, and that these conformations are further influenced by the DNA sequence context of the Pt-GG adduct.
Figures









Similar articles
-
Recognition of platinum-DNA adducts by HMGB1a.Biochemistry. 2012 Sep 25;51(38):7608-17. doi: 10.1021/bi3008577. Epub 2012 Sep 14. Biochemistry. 2012. PMID: 22950413
-
Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.J Mol Biol. 2007 Nov 9;373(5):1123-40. doi: 10.1016/j.jmb.2007.07.079. Epub 2007 Aug 23. J Mol Biol. 2007. PMID: 17900616 Free PMC article.
-
Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links.PLoS One. 2011;6(8):e23582. doi: 10.1371/journal.pone.0023582. Epub 2011 Aug 10. PLoS One. 2011. PMID: 21853154 Free PMC article.
-
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.Crit Rev Oncol Hematol. 2005 Jan;53(1):3-11. doi: 10.1016/j.critrevonc.2004.08.008. Crit Rev Oncol Hematol. 2005. PMID: 15607931 Review.
-
Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.Met Ions Biol Syst. 1996;33:105-41. Met Ions Biol Syst. 1996. PMID: 8742842 Review.
Cited by
-
Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein.Biophys J. 2012 May 16;102(10):2331-8. doi: 10.1016/j.bpj.2012.04.013. Epub 2012 May 15. Biophys J. 2012. PMID: 22677386 Free PMC article.
-
Disturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.BMC Struct Biol. 2013 Mar 22;13:4. doi: 10.1186/1472-6807-13-4. BMC Struct Biol. 2013. PMID: 23517640 Free PMC article.
-
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.Curr Cancer Drug Targets. 2012 May;12(4):356-71. doi: 10.2174/156800912800190901. Curr Cancer Drug Targets. 2012. PMID: 22385513 Free PMC article. Review.
-
Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.Pharmaceutics. 2022 Apr 28;14(5):954. doi: 10.3390/pharmaceutics14050954. Pharmaceutics. 2022. PMID: 35631543 Free PMC article. Review.
-
Differences in conformational dynamics of [Pt3(HPTAB)]6+-DNA adducts with various cross-linking modes.Nucleic Acids Res. 2009 Sep;37(17):5930-42. doi: 10.1093/nar/gkp618. Epub 2009 Aug 4. Nucleic Acids Res. 2009. PMID: 19654239 Free PMC article.
References
-
- Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005;53:L3–L11. - PubMed
-
- Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999;99:2467–2498. - PubMed
-
- Page JD, Husain I, Sancar A, Chaney SG. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry. 1990;29:1016–1024. - PubMed
-
- Jennerwein MM, Eastman A, Khokhar AR. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem. Biol. Interact. 1989;70:39–49. - PubMed
-
- Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998;54:770–777. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous